Results 181 to 190 of about 543,991 (236)

[Applicability of World Health Organization guidelines on self-care interventions for reproductive health in selected Latin American and Caribbean countriesAplicabilidade das diretrizes da Organização Mundial da Saúde sobre intervenções de autocuidado em saúde reprodutiva em países selecionados da América Latina e do Caribe]. [PDF]

Rev Panam Salud Publica
Gómez Ponce de León R, Perrotta GV, Pirsch S, Volij C, López A, Cejas C, Luis Rubinstein A, Narasimhan M, Serruya S.   +8 more
europepmc   +1 more source

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

Monodentate Phosphine Modulation in Cyclometallated Platinum(II) Complexes for Antileishmanial, Antiviral, and Antitumor Applications

ChemMedChem, EarlyView.
Schematic representation depicting the influence of phosphine ligand identity on the biological and physicochemical characteristics of Pt(II) complexes: PTA promotes antileishmanial activity, PPh2(Php–COOH) strengthens antiviral activity, and TCEP enhances fluorescence.
Antonio A. de Oliveira‐Neto, Gustavo Clauss, Jennyfer Castro, Marcus S. A. Garcia, Natasha M. Cassani, Bruna C. Sandim, Ana Laura C. Oliveira, Stephanie P. B. Reyes, Nádija N. P. da Silva, Fillipe V. Rocha, Ana C. G. Jardim, Danilo C. Miguel, Camilla Abbehausen   +12 more
wiley   +1 more source

[Subjectivities promoted by food and nutrition policies: The case of Comuna 1 Popular in Medellín, Colombia]. [PDF]

Salud Colect
Giraldo-López PA, Mancilla-López L, Muñoz-Duque LA.   +2 more
europepmc   +1 more source

Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis

Clinical Pharmacology &Therapeutics, EarlyView.
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted.
Tara Lazetic, Deanne Nixie R. Miao, Britt I. Drögemöller, Alain Dabdoub, Julia M. Abitbol   +4 more
wiley   +1 more source

Clinical practice guideline for the evaluation, treatment, and follow-up of children in contact with patients with pulmonary tuberculosis in Colombia. [PDF]

Colomb Med (Cali)
Benjumea-Bedoya D, Robledo-Restrepo JA, Arbelaez-Montoya MP, Estupiñán-Bohorquez AF, Sabella-Jimenez VS, Restrepo-Gouzy AV, Beltran-Arroyave CP, Bedoya-Giraldo J, Niederbacher-Velasquez J, Hurtado-Palacios IC, Cadavid-Álvarez LM, Vanegas-Rojas DE, Murillo Tenorio M, Paniagua-Saldarriaga L, Arteaga-Noriega AV, Sierra JM, Vélez CM, Botero-Garcés JH, Montes-Zuluaga FN, Villegas-Arbelaez E, Castaño-Osorio D, Andrade-Agudelo VH, Pedraza-Moreno LM, Cruz-Martínez OA, Llerena-Polo C, Gómez AJ, Gil-Artunduaga M, Cataño ML, Florez ID.   +28 more
europepmc   +1 more source

Repeated Intake of Grapefruit Juice Inhibits CYP2B6, CYP2C9, CYP2C19, and CYP3A4 while Lingonberry Powder Does Not Induce Major CYP Enzymes in Humans

Clinical Pharmacology &Therapeutics, EarlyView.
Grapefruit juice is a well‐established inhibitor of cytochrome P450 (CYP) 3A4, but its effects on other CYP enzymes or organic anion transporting polypeptides (OATPs) are not fully characterized in humans. Recently, lingonberry powder was shown to induce murine CYP enzymes. We investigated the effects of lingonberry powder and grapefruit juice on seven
Laura Aurinsalo, Outi Lapatto‐Reiniluoto, Mika Kurkela, Mikko Neuvonen, Eeva Moilanen, Mikko Niemi, Aleksi Tornio, Janne T. Backman   +7 more
wiley   +1 more source

[From global strategy to local consultation: A future vision of physical activity in primary care]. [PDF]

Aten Primaria
Romaguera M, Heras A, Solà Gonfaus M, de Pablo Màrquez B, Guarner M, Alòs F.   +5 more
europepmc   +1 more source

¿Un régimen especial para el concurso del consumidor? Notas sobre la liberación de deudas pendientes [PDF]

, 2010
García Vicente, José Ramón
core  

Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

Clinical Pharmacology &Therapeutics, EarlyView.
Fezolinetant is a first‐in‐class, selective, non‐hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause. In a phase 2b clinical study (n = 352), nine study participants experienced elevations in serum transaminases exceeding three times the upper limit of normal.
Jace C. Nielsen, Jeffrey L. Woodhead, Brett A. Howell, Lisl K. M. Shoda, Dolly A. Parasrampuria, Jiayin Huang, Megumi Iwai, Faith D. Ottery, Xuegong Wang, Marci English, Kentaro Miyazaki, Paul B. Watkins   +11 more
wiley   +1 more source